Results 11 to 20 of about 14,520 (202)

Fulvestrant-induced toxic epidermal necrolysis [PDF]

Anais Brasileiros de Dermatologia, 2019
Toxic epidermal necrolysis is a condition with massive keratinocyte apoptosis, and it is associated with high mortality rates. Fulvestrant, an estrogen receptor antagonist, is indicated in the treatment of estrogen receptor-positive metastatic breast ...
Macarena Morales-Conde, Natividad López-Ibáñez, Julio Calvete-Candenas, Francisco Manuel Ildefonso Mendonça   +3 more
doaj   +2 more sources

Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis

Cancer Management and Research, 2018
Tingting Zhang,1,* Fubin Feng,2,* Wenge Zhao,3 Yan Yao,3 Jinhui Tian,4 Chao Zhou,2 Chuanxin Zang,1 Cun Liu,1 Xue Wang,5 Changgang Sun2,6 1College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong ...
Zhang T, Feng F, Zhao W, Yao Y, Tian J, Zhou C, Zang C, Liu C, Wang X, Sun C   +9 more
doaj   +1 more source

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Pharmacogenomics and Personalized Medicine, 2011
Vineetha Koroth Edavana1, Xinfeng Yu1, Ishwori B Dhakal1, Suzanne Williams1, Baitang Ning2, Ian T Cook3, David Caldwell1, Charles N Falany3, Susan Kadlubar11Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences ...
Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S   +8 more
doaj   +1 more source

Insulin-like growth factor-binding protein-3 is induced by tamoxifen and fulvestrant and modulates fulvestrant response in breast cancer cells [PDF]

Frontiers in Oncology
IntroductionInsulin-like growth factor binding protein-3 (IGFBP-3) exerts varying effects on estrogen receptor alpha (ERα)-positive and triple-negative breast cancer (TNBC) cells. In ERα-positive cells, IGFBP-3 is antiproliferative and proapoptotic.
Keenan L. Flynn, Yan Zheng, Janel Y. Sowers, Nefretiri J. T. Masangya, Kevin D. Houston   +4 more
doaj   +2 more sources

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

, 2022
PURPOSE: This phase II study investigated daily or weekly sapanisertib (a selective dual inhibitor of mTOR complexes 1 and 2) in combination with fulvestrant.
Jerez, Yolanda, Lahuerta, Ainhara, Alonso-Romero, José Luis, García-Sáenz, José Á., Slamon, Dennis, Leonard, E Jane, Alonso-Romero, Jose L., Alonso-Romero, Jose L, Carrasco, Eva, González-Santiago, Santiago, Ramos, Manuel, Vincent, Sylvie, Ferrer, Nieves, Galinsky, Kevin, Chen, Jingjing, García-Sáenz, José Á, Neuwirth, Rachel, Martínez-Jáñez, Noelia, Cubedo, Ricardo, Antón, Antonio, Leonard, E. Jane   +20 more
core   +1 more source

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

BMC Cancer, 2021
Background There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. Methods We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from February 2015 to ...
Daniel C. Beachler, Cynthia de Luise, Aziza Jamal-Allial, Ruihua Yin, Devon H. Taylor, Ayako Suzuki, James H. Lewis, James W. Freston, Stephan Lanes   +8 more
doaj   +1 more source

Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. [PDF]

, 2021
Lessons learnedFulvestrant is a selective estrogen receptor (ER)-downregulating antiestrogen that blocks ER transcriptional activity and is approved for ER-positive breast cancer.
Lewis, Lionel, Romo, Bianca, Marotti, Jonathan, Shee, Kevin, Kisselev, Alexei, Miller, Todd, Schwartz, Gary   +6 more
core   +1 more source

Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor–positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial [PDF]

, 2019
Importance Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating ...
Sarker, S.-J., Mousa, K, Harper-Wynne, Catherine, Saura, C, Schenker, M., Lee, Keun Seok, Conibear, J, Kristeleit, Hartmut, Moosa, A, Coetzee, C, Prendergast, A., Lawrence, C, Makris, A, Schmid, Peter, Chan, Stephen, Nemsadze, G, Nemsadze, Gia, Ferreira, M., Harper-Wynne, C., Kristeleit, H, Kendall, A., Perelló, Antonia, Schenker, M, Mousa, Kelly, Lee, KS, Cortés, Javier, Ruiz, I., Mousa, K., Brown, Anne Kendall, Zaiss, M., Conibear, J., Sarker, S-J, Dubey, S., Harper-Wynne, C, Kuemmel, Sherko, Prendergast, A, Saura, Cristina, Schmid, P., Lawrence, Cheryl, Zaiss, M, Ruiz, Isabel, Conibear, John, Shepherd, Christopher J., Perello, A., Perelló, A, Grenier, J, Makris, A., Marosics, Patricia, Mahr, K., Brown, J, Chan, S., Marosics, P, Oelmann, Elisabeth, Moosa, Atiyyah, Brunt, A., Moosa, A., Schenker, Michael, Kuemmel, S., Kristeleit, H., Coetzee, C., Schmid, P, Ferreira, M, Prendergast, Aaron, Cortés, J, Cortes, J., Shepherd, C., Kuemmel, S, Oelmann, E., Coetzee, Carike, Saura, C., Brown, J., Zaiss, Matthias, Kendall, A, Lawrence, C., Brunt, AM, Ruiz, I, Lee, K.S., Brown, Janet, Marosics, P., Grenier, Julien, Chan, S, Sohn, J, Dubey, S, Oelmann, E, Shepherd, CJ, Brunt, Adrian M., Nemsadze, G., Ferreira, Marta, Sohn, J., Máhr, K, Sarker, Shah-Jalal, Dubey, Sidharth, Sohn, Joohyuk, Grenier, J., Makris, Andreas, Máhr, Károly   +95 more
core   +1 more source

Quality of life with palbociclib plus fulvestrant placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Therapeutic Advances in Medical Oncology, 2023
Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2− advanced breast cancer (ABC).
Ariadna Tibau, M. Teresa Martínez, Manuel Ramos, Luis De La Cruz-Merino, Ana Santaballa, Miriam O’Connor, Noelia Martínez-Jañez, Fernando Moreno, Isaura Fernández, Juan Antonio Virizuela, Jesús Alarcón, Juan de La Haba-Rodríguez, Pedro Sánchez-Rovira, Cinta Rosa Albacar, Coralia Bueno Muiño, Catherine Kelly, Maribel Casas, Susana Bezares, Libertad Rosell, Joan Albanell   +19 more
doaj   +1 more source

Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome

Cancer Research, Statistics, and Treatment, 2020
Background: Fulvestrant has been shown to improve survival in hormone-positive, HER2-negative advanced breast cancer (ABC). There is no study on fulvestrant from India.
Indhuja Muthiah Vaikundaraja, Manikandan Dhanushkodi, Venkatraman Radhakrishnan, Jayachandran Perumal Kalaiarasi, Nikita Mehra, Arun Kumar Rajan, Gangothri Selvarajan, Siva Sree Kesana, Balasubramanian Ananthi, Priya Iyer, Geetha Senguttuvan, Manjula Rao, Arvind Krishnamurthy, Sridevi Velusamy, Hemanth Raj, Rama Ranganathan, Shirley Sundersingh, Selvaluxmy Ganesarajah, Trivadi S Ganesan, Tenali Gnana Sagar   +19 more
doaj   +1 more source